API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.contractpharma.com/contents/view_breaking-news/2023-08-31/lonza-vertex-break-ground-for-cell-therapy-mfg-facility/
https://endpts.com/two-aurinia-execs-are-out-and-crisprs-operations-chief-isnt-far-behind-biogen-ms-leader-jumps-to-eli-lilly-partner/
https://www.nasdaq.com/articles/vertex-vrtx-cf-drug-gets-fda-expanded-label-for-toddlers
https://endpts.com/fda-lifts-hold-on-vertexs-diabetes-stem-cell-therapy-after-just-two-months-under-the-microscope/
https://endpts.com/teva-chief-raids-vertex-for-his-new-global-head-of-research-and-development/
https://endpts.com/on-bluebirds-heels-crispr-therapeutics-and-vertex-take-the-air-with-interim-crispr-blood-cell-therapy-data/
https://endpts.com/after-60m-vertex-deal-group-of-catalyst-shareholders-claims-biotech-couldve-sold-assets-three-years-ago/
https://www.fiercebiotech.com/biotech/aiming-be-biggest-biotech-boston-vertex-plots-500-person-cell-and-genetic-therapy-rd-center
https://www.bloomberg.com/news/articles/2022-05-02/vertex-falls-after-fda-pauses-diabetes-study-in-surprise-move
https://www.fiercebiotech.com/biotech/abbvies-cystic-fibrosis-long-game-doesnt-pay-galapagos-med-fails-triple-combo
https://endpts.com/acadias-prized-pain-drug-from-52m-buyout-flops-its-first-test/
https://endpts.com/orbimed-backed-biotech-looks-to-challenge-vertex-in-cystic-fibrosis-by-drugging-the-undruggable/
https://www.statnews.com/2022/03/31/vertexs-non-opioid-painkiller-meets-goals-in-mid-stage-studies/
https://www.fiercepharma.com/pharma/what-competition-vertex-touts-trikafta-s-competitive-edge-back-strong-2021
https://endpts.com/crispr-viacyte-beat-vertex-to-the-clinic-with-diabetes-cell-therapy-that-evades-the-immune-system/
https://www.biopharmadive.com/news/boehringer-ingelheim-cystic-fibrosis-gene-therapy/608488/
https://www.fiercebiotech.com/biotech/vertex-s-rare-lung-disease-drug-hits-phase-2-goal-but-still-winds-up-scrapheap
https://www.businesswire.com/news/home/20210610005939/en/Vertex-Announces-Primary-Endpoint-Achieved-in-Phase-2-Study-of-VX-864-in-Alpha-1-Antitrypsin-Deficiency
https://endpts.com/cf-foundation-backs-a-new-round-for-a-biotech-upstart-out-to-rival-the-mighty-vertex/
https://www.fiercebiotech.com/biotech/vertex-s-success-kills-off-savara-s-experimental-cystic-fibrosis-drug-hopes
http://www.pharmatimes.com/news/vertex_and_nhs_wales_agree_on_kaftrio_reimbursement_1345325
https://endpts.com/david-hallal-bags-another-whopper-round-looking-to-recruit-more-cell-and-gene-therapy-upstarts-to-elevate-basecamp/
http://www.pharmafile.com/news/533429/vertexs-cystic-fibrosis-portfolio-be-made-available-across-northern-ireland-and-wales
https://www.fiercepharma.com/manufacturing/gsk-opens-130m-continuous-production-facilities-singapore?utm_source=internal&utm_medium=rss
https://www.fiercebiotech.com/biotech/pfizer-s-dmd-gene-therapy-safety-data-hand-advantage-to-sarepta
https://endpts.com/the-top-10-blockbuster-drugs-in-the-late-stage-pipeline-evaluate-adds-6-new-therapies-to-heavy-hitter-list/
https://www.fiercepharma.com/pharma/investors-fall-short-effort-to-learn-more-about-link-between-ceo-pay-drug-prices
https://pharmaphorum.com/news/vertexs-orkambi-cf-drug-okayed-for-funding-in-australia/